Medical 21

Synthetic regenerative graft developer Medical 21 files for a $25 million IPO IPO Overview Medical 21, which is developing a synthetic regenerative graft for coronary bypass surgery, filed on Thursday with the SEC to raise up to $25 million in... Read more